Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

Amin DN, Campbell MR, Moasser MM.

Semin Cell Dev Biol. 2010 Dec;21(9):944-50. doi: 10.1016/j.semcdb.2010.08.007. Epub 2010 Sep 9. Review.

2.

Targeting HER proteins in cancer therapy and the role of the non-target HER3.

Hsieh AC, Moasser MM.

Br J Cancer. 2007 Aug 20;97(4):453-7. Epub 2007 Jul 31. Review.

3.

HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.

Kol A, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Lamberts LE, Bensch F, de Vries EG, Schröder CP.

Pharmacol Ther. 2014 Jul;143(1):1-11. doi: 10.1016/j.pharmthera.2014.01.005. Epub 2014 Feb 7. Review.

PMID:
24513440
4.

Regulation of ERBB3/HER3 signaling in cancer.

Mujoo K, Choi BK, Huang Z, Zhang N, An Z.

Oncotarget. 2014 Nov 15;5(21):10222-36. Review.

5.

HER3/ErbB3, an emerging cancer therapeutic target.

Zhang N, Chang Y, Rios A, An Z.

Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):39-48. doi: 10.1093/abbs/gmv103. Epub 2015 Oct 24. Review.

PMID:
26496898
6.

The upgraded role of HER3 and HER4 receptors in breast cancer.

Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP.

Crit Rev Oncol Hematol. 2010 May;74(2):73-8. doi: 10.1016/j.critrevonc.2009.04.011. Epub 2009 May 30. Review.

PMID:
19481955
7.

A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.

Claus J, Patel G, Ng T, Parker PJ.

Biochem Soc Trans. 2014 Aug;42(4):831-6. doi: 10.1042/BST20140043. Review.

PMID:
25109965
8.

Role of erbB3 receptors in cancer therapeutic resistance.

Lee Y, Ma J, Lyu H, Huang J, Kim A, Liu B.

Acta Biochim Biophys Sin (Shanghai). 2014 Mar;46(3):190-8. doi: 10.1093/abbs/gmt150. Epub 2014 Jan 20. Review.

PMID:
24449784
9.

Targeting the HER-kinase axis in cancer.

Gross ME, Shazer RL, Agus DB.

Semin Oncol. 2004 Feb;31(1 Suppl 3):9-20. Review.

PMID:
15052539
10.

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

Arteaga CL, Engelman JA.

Cancer Cell. 2014 Mar 17;25(3):282-303. doi: 10.1016/j.ccr.2014.02.025. Review.

11.

Update on HER-kinase-directed therapy in prostate cancer.

Gross ME, Jo S, Agus DB.

Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64. Review.

PMID:
16163160
12.

HER3 as a Therapeutic Target in Cancer.

Karachaliou N, Lazzari C, Verlicchi A, Sosa AE, Rosell R.

BioDrugs. 2017 Feb;31(1):63-73. doi: 10.1007/s40259-016-0205-2. Review.

PMID:
28000159
13.

The role of HER3 in gastric cancer.

Wang L, Yuan H, Li Y, Han Y.

Biomed Pharmacother. 2014 Jul;68(6):809-12. doi: 10.1016/j.biopha.2014.08.011. Epub 2014 Aug 20. Review.

PMID:
25194439
14.

Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance.

Temraz S, Mukherji D, Shamseddine A.

Crit Rev Oncol Hematol. 2016 May;101:151-7. doi: 10.1016/j.critrevonc.2016.03.009. Epub 2016 Mar 10. Review.

PMID:
27017409
15.

Role of HER2/HER3 co-receptor in breast carcinogenesis.

Way TD, Lin JK.

Future Oncol. 2005 Dec;1(6):841-9. Review.

PMID:
16556064
16.

Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.

Monteiro Ide P, Madureira P, de Vasconscelos A, Pozza DH, de Mello RA.

Pharmacogenomics. 2015;16(3):257-71. doi: 10.2217/pgs.14.133. Review.

PMID:
25712189
17.

Targeting HER receptors in cancer.

Ocaña A, Pandiella A.

Curr Pharm Des. 2013;19(5):808-17. Review.

PMID:
22973952
18.
19.

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

Baselga J, Swain SM.

Nat Rev Cancer. 2009 Jul;9(7):463-75. doi: 10.1038/nrc2656. Epub 2009 Jun 18. Review.

PMID:
19536107
20.

ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.

Stern DF.

J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):215-23. doi: 10.1007/s10911-008-9083-7. Epub 2008 May 3. Review.

PMID:
18454306

Supplemental Content

Support Center